Health & Personal Care
HIGH
FDA DRUG
Breckenridge Recalls Duloxetine Capsules Over Chemical Hazard
Breckenridge Pharmaceutical, Inc. recalled 7,389 bottles of Duloxetine Delayed-Release Capsules on November 24, 2025. The recall stems from CGMP deviations and the presence of N-nitroso-duloxetine impurity above FDA limits. Consumers should stop using the product immediately and contact healthcare providers for guidance.
DULOXETINE
CGMP Deviations;